Gapping down
In reaction to disappointing earnings/guidance: CREE -12.9%, AGU -5.5%, STZ -2.9%
Other news: WILN -13.1% (commenced litigation against several companies), TWI -8.7% (light volume, may be attributed to AGU outlook), NLNK -5.7% (announced appointment of Jack Henneman as Chief Financial Officer following departure of Gordon H. Link, Jr.), DNDN -5.2% (still checking), PTLA -3.6% (Portola Pharma files for 10 mln share common stock shelf offering; commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000), GPRO -2.5% (cont pre-mkt vol activity), RDUS -1.7% (announces proposed public offering), RVNC -1.5% (announced expected delay in results from Phase 3 study of RT001 for the treatment of lateral canthal (crow's feet) lines), MRD -1.5% (filed for ~27.8 mln share common stock offering by selling shareholders), POT -1% (following AGU earnings)
Analyst comments: DNDN -5.2% (target cut to $1 from $2 at Citi), ENPH -2.4% (downgraded to Neutral from Buy at BofA/Merrill), JPM -1% (downgraded to Neutral from Buy at UBS), MSI -0.7% (downgraded to Neutral from Buy at Citigroup), X -0.5% (downgraded to Hold from Buy at KeyBanc Capital Mkts), ETN -0.5% (downgraded to Perform from Outperform at Oppenheimer)
In reaction to disappointing earnings/guidance: CREE -12.9%, AGU -5.5%, STZ -2.9%
Other news: WILN -13.1% (commenced litigation against several companies), TWI -8.7% (light volume, may be attributed to AGU outlook), NLNK -5.7% (announced appointment of Jack Henneman as Chief Financial Officer following departure of Gordon H. Link, Jr.), DNDN -5.2% (still checking), PTLA -3.6% (Portola Pharma files for 10 mln share common stock shelf offering; commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000), GPRO -2.5% (cont pre-mkt vol activity), RDUS -1.7% (announces proposed public offering), RVNC -1.5% (announced expected delay in results from Phase 3 study of RT001 for the treatment of lateral canthal (crow's feet) lines), MRD -1.5% (filed for ~27.8 mln share common stock offering by selling shareholders), POT -1% (following AGU earnings)
Analyst comments: DNDN -5.2% (target cut to $1 from $2 at Citi), ENPH -2.4% (downgraded to Neutral from Buy at BofA/Merrill), JPM -1% (downgraded to Neutral from Buy at UBS), MSI -0.7% (downgraded to Neutral from Buy at Citigroup), X -0.5% (downgraded to Hold from Buy at KeyBanc Capital Mkts), ETN -0.5% (downgraded to Perform from Outperform at Oppenheimer)